Top of page

Healthcare & Life Sciences

Industry

Filters

Royalty Pharma $2.5 billion IPO

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…

Generation Bio $230 million IPO

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering…

Legend Biotech $487 million IPO

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend…
Back to top